Gaush Meditech (HKSE:02407) Beneish M-Score: -2.48 (As of Jul. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02407 Gaush Meditech Ltd HKSE:02407
67 GF Score
Price HK$4.93
GF Value HK$13.39
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Gaush Meditech Beneish M-Score?

Gaush Meditech HKSE:02407 +0.61% 67 Beneish M-Score is -2.48 as of Jul. 20, 2026. GuruFocus rates HKSE:02407 with a GF Score™ of 67/100 and a GF Value™ of HK$13.39 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 762 Medical Devices & Instruments companies, Gaush Meditech ranks worse than 59.97% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.48 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Gaush Meditech's Beneish M-Score or its related term are showing as below:

HKSE:02407' s Beneish M-Score Range Over the Past 10 Years
Min: -3.3   Med: -2.58   Max: -2.16
Current: -2.48

During the past 7 years, the highest Beneish M-Score of Gaush Meditech was -2.16. The lowest was -3.30. And the median was -2.58.


Gaush Meditech Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Gaush Meditech's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gaush Meditech Beneish M-Score Chart

Gaush Meditech Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial -3.30 -3.27 -2.58 -2.16 -2.48

Gaush Meditech Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.58 0.00 -2.16 0.00 -2.48

HKSE:02407 vs ABT, SYK, MDT: Beneish M-Score Comparison

For the Medical Devices subindustry, Gaush Meditech's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gaush Meditech Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Gaush Meditech's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Gaush Meditech's Beneish M-Score falls into.


HKSE:02407
67GF Score
Gaush Meditech Ltd HKSE:02407
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gaush Meditech Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Gaush Meditech for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0462+0.528 * 1.0124+0.404 * 1.0585+0.892 * 0.9999+0.115 * 1.0314
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.1459+4.679 * -0.018309-0.327 * 0.9052
=-2.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was HK$326 Mil.
Revenue was HK$1,525 Mil.
Gross Profit was HK$700 Mil.
Total Current Assets was HK$1,195 Mil.
Total Assets was HK$2,899 Mil.
Property, Plant and Equipment(Net PPE) was HK$160 Mil.
Depreciation, Depletion and Amortization(DDA) was HK$100 Mil.
Selling, General, & Admin. Expense(SGA) was HK$463 Mil.
Total Current Liabilities was HK$498 Mil.
Long-Term Debt & Capital Lease Obligation was HK$395 Mil.
Net Income was HK$106 Mil.
Gross Profit was HK$0 Mil.
Cash Flow from Operations was HK$159 Mil.
Total Receivables was HK$312 Mil.
Revenue was HK$1,525 Mil.
Gross Profit was HK$708 Mil.
Total Current Assets was HK$1,229 Mil.
Total Assets was HK$2,740 Mil.
Property, Plant and Equipment(Net PPE) was HK$132 Mil.
Depreciation, Depletion and Amortization(DDA) was HK$87 Mil.
Selling, General, & Admin. Expense(SGA) was HK$404 Mil.
Total Current Liabilities was HK$546 Mil.
Long-Term Debt & Capital Lease Obligation was HK$386 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(326.335 / 1524.879) / (311.976 / 1525.06)
=0.214007 / 0.204566
=1.0462

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(708.282 / 1525.06) / (699.51 / 1524.879)
=0.464429 / 0.458731
=1.0124

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1194.865 + 159.818) / 2898.855) / (1 - (1228.652 + 132.404) / 2739.979)
=0.532683 / 0.50326
=1.0585

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1524.879 / 1525.06
=0.9999

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(87.488 / (87.488 + 132.404)) / (100.373 / (100.373 + 159.818))
=0.397868 / 0.385767
=1.0314

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(462.852 / 1524.879) / (403.964 / 1525.06)
=0.303534 / 0.264884
=1.1459

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((394.514 + 498.418) / 2898.855) / ((385.905 + 546.45) / 2739.979)
=0.308029 / 0.340278
=0.9052

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(106.262 - 0 - 159.338) / 2898.855
=-0.018309

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Gaush Meditech has a M-score of -2.48 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.48 mean?
Gaush Meditech (HKSE:02407) has a Beneish M-Score of -2.48 as of Jul. 20, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Gaush Meditech and its competitors. According to the industry distribution chart, Gaush Meditech ranks #457 out of 762 companies in the Medical Devices & Instruments industry, placing it in the top 60%.
Is Gaush Meditech's Beneish M-Score too high?
Gaush Meditech's current Beneish M-Score is -2.48. Based on the distribution chart, Gaush Meditech ranks #457 out of 762 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Gaush Meditech has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Gaush Meditech's Beneish M-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Gaush Meditech ranks #457 out of 762 companies for Beneish M-Score. This places Gaush Meditech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Gaush Meditech and its competitors. Gaush Meditech's current Beneish M-Score is -2.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gaush Meditech stock overvalued right now?
Based on GuruFocus' analysis, Gaush Meditech (HKSE:02407) is currently considered Possible Value Trap. The stock's GF Value™ is HK$13.39, compared to a current price of HK$4.93 — trading 63.2% below its estimated fair value. The current Beneish M-Score is -2.48. Gaush Meditech's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Gaush Meditech (HKSE:02407), the current Beneish M-Score is -2.48 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gaush Meditech (HKSE:02407) Overvalued in 2026?

Based on GuruFocus' analysis, Gaush Meditech stock appears to be undervalued. The current stock price of HK$4.93 is trading 63.2% below its estimated GF Value™ of HK$13.39. GuruFocus considers Gaush Meditech to be Possible Value Trap.

Key valuation signals for HKSE:02407:

  • Beneish M-Score: -2.48
  • GF Value™: HK$13.39 vs. price of HK$4.93 (63.2% below fair value)
  • GF Score™: 67/100 with 3 warning signs

No single metric tells the full story. See the HKSE:02407 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Gaush Meditech Business Description

Other Exchanges F7Y:Germany
Address No.11 Dongzhimen South Avenue, Room 1901, Building A, Zhonghui Plaza, Dongcheng District, Beijing, CHN
Gaush Meditech Ltd is a provider of a broad spectrum of manufacture and sale ophthalmic medical devices and provision of technical services. The segments of the company include Proprietary products segment that derives maximum revenue, develops and produces surgical equipment and related supporting software, intra-optical lens, ophthalmic disease diagnosis and treatment equipment and related supporting consumables independently; Distribution products segment sells multi-function diagnostic equipment, ocular fundus diagnosis, surgical and treatment equipment and related supporting consumables produced by ophthalmic medical equipment manufacturers; Technical services segment provides warranty services, maintenance services and other related consumables; and Others segment.
67GF Score

Get the complete analysis for HKSE:02407

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$4.93
Price
HK$13.39
GF Value